

174. Roh, W., Geffen, Y., Cha, H., Miller, M., Anand, S., Kim, J., Heiman, D.I., Gainor, J.F., Laird, P.W., Cherniack, A.D., et al. (2022). High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. *Cancer Res.* 82, 3917–3931. <https://doi.org/10.1158/0008-5472.CAN-22-0432>.
175. Hunter, T. (2007). The age of crosstalk: phosphorylation, ubiquitination, and beyond. *Mol. Cell* 28, 730–738. <https://doi.org/10.1016/j.molcel.2007.11.019>.
176. Woodsmith, J., Kamburov, A., and Stelzl, U. (2013). Dual coordination of post translational modifications in human protein networks. *PLoS Comput. Biol.* 9, e1002933. <https://doi.org/10.1371/journal.pcbi.1002933>.
177. Beltrao, P., Bork, P., Krogan, N.J., and van Noort, V. (2013). Evolution and functional cross-talk of protein post-translational modifications. *Mol. Syst. Biol.* 9, 714. <https://doi.org/10.1002/msb.201304521>.
178. Bludau, I., Willems, S., Zeng, W.-F., Strauss, M.T., Hansen, F.M., Tanzer, M.C., Karayel, O., Schulman, B.A., and Mann, M. (2022). The structural context of posttranslational modifications at a proteome-wide scale. *PLoS Biol.* 20, e3001636. <https://doi.org/10.1371/journal.pbio.3001636>.
179. Babur, Ö., Melrose, A.R., Cunliffe, J.M., Klimek, J., Pang, J., Sepp, A.-L.I., Zilberman-Rudenko, J., Tassi Yunga, S., Zheng, T., Parra-Izquierdo, I., et al. (2020). Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs. *Blood* 136, 2346–2358. <https://doi.org/10.1182/blood.2020005496>.
180. Babur, Ö., Ngo, A.T.P., Rigg, R.A., Pang, J., Rub, Z.T., Buchanan, A.E., Mitrugno, A., David, L.L., McCarty, O.J.T., Demir, E., et al. (2018). Platelet procoagulant phenotype is modulated by a p38-MK2 axis that regulates RTN4/Nogo proximal to the endoplasmic reticulum: utility of pathway analysis. *Am. J. Physiol. Cell Physiol.* 314, C603–C615. <https://doi.org/10.1152/ajpcell.00177.2017>.
181. Joshi, S.K., Nechiporuk, T., Bottomly, D., Piehowski, P.D., Reisz, J.A., Pittsenbarger, J., Kaempf, A., Gosline, S.J.C., Wang, Y.-T., Hansen, J.R., et al. (2021). The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. *Cancer Cell* 39, 999–1014.e8. <https://doi.org/10.1016/j.ccell.2021.06.003>.
182. Khadka, P., Reitman, Z.J., Lu, S., Buchan, G., Gionet, G., Dubois, F., Carvalho, D.M., Shih, J., Zhang, S., Greenwald, N.F., et al. (2022). PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. *Nat. Commun.* 13, 604. <https://doi.org/10.1038/s41467-022-28198-8>.
183. Keshishian, H., McDonald, E.R., 3rd, Mundt, F., Melanson, R., Krug, K., Porter, D.A., Wallace, L., Forestier, D., Rabasha, B., Marlow, S.E., et al. (2021). A highly multiplexed quantitative phosphosite assay for biology and preclinical studies. *Mol. Syst. Biol.* 17, e10156. <https://doi.org/10.15252/msb.202010156>.
184. Johnson, B.E., Creason, A.L., Stommel, J.M., Keck, J.M., Parmar, S., Betts, C.B., Blucher, A., Boniface, C., Bucher, E., Burlingame, E., et al. (2022). An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. *Cell Rep. Med.* 3, 100525. <https://doi.org/10.1016/j.xcrm.2022.100525>.
185. Zhao, M., Scott, S., Evans, K.W., Yuca, E., Saridogan, T., Zheng, X., Wang, H., Korkut, A., Cruz Pico, C.X., Demirhan, M., et al. (2021). Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer. *Clin. Cancer Res.* 27, 1681–1694. <https://doi.org/10.1158/1078-0432.CCR-20-3017>.